GradisharWJ, AndersonBO, BalassanianR, et al.Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in ocology. J Natl Compr Canc Netw, 2016; 14:324–354.
2.
HornbergerJC, ChienR. Meta-analysis of the decision impact of the 21-gene breast cancer recurrence score® in clinical practice. Breast, 2011; 20(suppl 1):S44.
3.
ShakS, PetkovVI, MillerDP, et al.Breast cancer specific survival in 38,568 patients with node negative hormone receptor positive invasive breast cancer and Oncotype DX recurrence score results in the SEER database. Poster (P5-15-01) presented at 2015 San Antonio Breast Cancer Conference: San Antonio, TX, 2015.
4.
SimonRM, PaikS, HayesDF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst, 2009; 101:1446–1452.
5.
HarrisLN, IsmailaN, McShaneLM, et al.Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 2016; 34:1134–1150.
6.
PaikS, TangG, ShakS, et al.Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol, 2006; 24:3726–3734.
7.
AlbainKS, BarlowWE, ShakS, et al.Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol, 2010; 11:55–65.
8.
SparanoJA, GrayRJ, MakowerDF, et al.Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med, 2015; 373:2005–2014.
9.
AlvaradoMD, PrasadC, RothneyM, et al.A prospective comparison of the 21-gene Recurrence Score and the PAM50-based Prosigna in estrogen receptor-positive early-stage breast cancer. Adv Ther, 2015; 32:1237–1247.
10.
DowsettM, SestakI, Lopez-KnowlesE, et al.Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol, 2013; 31:2783–2790.
11.
SpringLM, GuptaA, ReynoldsKL, et al.Neoadjuvant endocrine therapy for estrogen receptor positive breast cancer: a systematic review and meta-analysis. JAMA Oncol, 2016. DOI: 10.1001/jamaoncol.2016.1897.
